<DOC>
	<DOCNO>NCT01432444</DOCNO>
	<brief_summary>The purpose study compare retrospective hospitalization rate schizophrenic patient treat oral antipsychotic prospective hospitalization rate patient treat IM depot aripiprazole .</brief_summary>
	<brief_title>Open-label Study Compare Hospitalization Rates Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole</brief_title>
	<detailed_description>Nonadherence antipsychotic medication remain frequent cause relapse among patient schizophrenia , increase hospitalization rate , hospitalization day , hospitalization cost . Among hospitalized adult , schizophrenia fourth commonly diagnose illness seventh long mean duration hospital stay US . Frequent relapse hospitalization affect quality life patient . Long-acting injection ( intramuscular depot ) antipsychotic medication mean treatment adherence increase quality life patient schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Subjects able provide write informed consent . If IRB require consent legally acceptable representative addition subject , required consent must obtain prior protocolrequired procedure . Male female subject 18 65 year age , inclusive . Current diagnosis schizophrenia define DSMIVTR criterion history illness least 1 year ( 12 month ) . Subjects investigator 's judgment would benefit extended treatment longacting injectable formulation . Subjects least 1 inpatient psychiatric hospitalization 4 year ( 48 month ) prior screen , manage outpatient 4 week prior enter study . Subjects must oral antipsychotic treatment full 7 month prior screen phase . Subjects show response previous antipsychotic treatment . Subjects understand nature trial able follow protocol requirement . Prisoners subject compulsorily detain ( involuntarily incarcerate ) , incarcerate past 7 month reason must enrol trial . Subjects may require potent CYP2D6 CYP3A4 inhibitor CYP3A4 inducer trial . Any subject require may need antipsychotic medication course trial , allow rescue medication . Subjects know allergic , intolerant , unresponsive prior treatment aripiprazole quinolinones . Subjects history hypersensitivity antipsychotic agent . Subjects deem intolerant receive injectable treatment . Subjects received electroconvulsive therapy within last 7 month prior screen . Subjects history neuroleptic malignant syndrome clinically significant tardive dyskinesia assess investigator . Subjects current DSMIVTR diagnosis schizophrenia , include schizoaffective disorder , major depressive disorder , bipolar disorder , delirium , dementia , amnestic cognitive disorder . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid , antisocial personality disorder . Subjects require hospitalization psychiatric reason 4 week prior sign ICF screen period . Subjects without least 1 inpatient psychiatric hospitalization last 4 year ( 48 month ) prior screen . Subjects meet DSMIVTR criterion significant substance use disorder within 3 month prior screen . Subjects consider treatmentresistant antipsychotic medication clozapine . Treatment longacting injectable antipsychotic last dose within 7 month prior screen . Subjects treat oral antipsychotic 7 month prior screen . Subjects significant risk commit suicide Subjects history evidence medical condition would expose undue risk significant adverse event interfere assessment safety efficacy course trial . Females pregnant lactating , sexually active male female commit utilizing birth control trial 180 day follow trial . Abnormal laboratory physical examination result indicate condition may interfere result study pose safety risk subject . Subjects previously enrol aripiprazole IM depot clinical study , except subject enter trial Canadian 3111284 trial . Subjects participate clinical trial investigational agent within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>